ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia

INGLEWOOD, Calif., Oct. 17, 2022 /PRNewswire/ -- ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is pleased to announce the completion of a Master Services...

Click to view original post